



## OPEN ACCESS

APPROVED BY  
Giuseppe Giaccone,  
Cornell University, United States

\*CORRESPONDENCE  
Frontiers Editorial Office  
✉ [research.integrity@frontiersin.org](mailto:research.integrity@frontiersin.org)

RECEIVED 11 March 2025  
ACCEPTED 11 March 2025  
PUBLISHED 25 March 2025

CITATION  
Frontiers Editorial Office (2025) Retraction:  
Dihydroartemisinin suppresses the  
tumorigenesis and cycle progression  
of colorectal cancer by targeting  
CDK1/CCNB1/PLK1 signaling.  
*Front. Oncol.* 15:1591122.  
doi: 10.3389/fonc.2025.1591122

COPYRIGHT  
© 2025 Frontiers Editorial Office. This is an  
open-access article distributed under the terms  
of the [Creative Commons Attribution License  
\(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction  
in other forums is permitted, provided the  
original author(s) and the copyright owner(s)  
are credited and that the original publication  
in this journal is cited, in accordance with  
accepted academic practice. No use,  
distribution or reproduction is permitted  
which does not comply with these terms.

# Retraction: Dihydroartemisinin suppresses the tumorigenesis and cycle progression of colorectal cancer by targeting CDK1/CCNB1/PLK1 signaling

Frontiers Editorial Office\*

## A Retraction of the Original Research article

[Dihydroartemisinin suppresses the tumorigenesis and cycle progression of colorectal cancer by targeting CDK1/CCNB1/PLK1 signaling](#)

by Yi Y-C, Liang R, Chen X-Y, Fan H-N, Chen M, Zhang J and Zhu J-S (2021). *Front. Oncol.* 11:768879. doi: 10.3389/fonc.2021.768879

Following publication, concerns were raised regarding the integrity of the images in the published figures. The authors failed to provide a satisfactory explanation during the investigation, which was conducted in accordance with Frontiers' policies. As a result, the data and conclusions of the article have been deemed unreliable and the article has been retracted.

This retraction was approved by the Chief Editors of Frontiers in Oncology and the Chief Executive Editor of Frontiers. The authors do not agree to this retraction.